The start-up Eisbach Bio in the IZB near Munich receives 6.7 million euros from the Bavarian state government for the development of a COVID-19 therapeutics
- Photo Info
- Download
- One additional media item
One document
The start-up Eisbach Bio in the IZB near Munich receives 6.7 million euros from the Bavarian state government
The aim is the development of targeted SARS-CoV-2 antivirals
Enclosed we send you the news of the Innovation and Start-up Center Biotechnology. We would be pleased if you would consider the message in your news coverage. Should you write a contribution, we would be very pleased if you would send us a link.
Press Release
The start-up Eisbach Bio in the IZB near Munich receives 6.7 million euros from the Bavarian state government
The aim is the development of targeted SARS-CoV-2 antivirals
Eisbach Bio, a biotechnology company targeting the molecular machines that drive human disease, already received funding of 8 million euros from the German Federal Ministry of Education and Research (BMBF) in July 2021. At the end of October 2021, the start-up announces another financial support from the Bavarian Ministry of Economic Affairs, Regional Development and Energy (StMWi) for the preclinical and clinical development of a proprietary SARS-CoV-2 helicase inhibitor and its backups. The funding of 6.7 million euros will support the development of the Company’s COVID-19 therapeutics and maintain the competitiveness of the biotech scene in Bavaria as part of the BayTherapie 2020 program. Eisbach Bio is located in the Innovation and Start-up Center Biotechnology (IZB) in Martinsried near Munich.
Eisbach’s CEO, Dr. Adrian Schomburg, commented: “Our team is grateful to receive state support for the development of our drug candidates. The biotech scene in Bavaria and beyond will benefit from this project. Our research progress illustrates how Bavarian companies joined the fight against COVID-19, taking a leading role in driving innovation and identifying therapeutic solutions.”
Prof. Andreas Ladurner, Eisbach’s CSO, added: “We are determined to deliver a sustainable drug with a good safety profile. The funded BayTherapie2020 program will allow us to allocate more resources to the research and development of EIS4363, greatly increasing our chances of developing a much-needed novel antiviral for the global community.”
The financial support adds to the Company’s government-funded grants for the development of its novel targeted antivirals. Eisbach is rapidly progressing its IND-enabling work and expects to initiate Phase I clinical trials for its nominated COVID-19 asset in Q2, 2022.
Eisbach aims to bring a safe, sustainable and targeted antiviral drug with specific activity against the SARS-CoV-2 virus into the clinic to lower disease progression and help end the pandemic globally. Using its molecular machine expertise, the Company developed EIS4363, a small molecule inhibitor of the SARS-CoV-2 helicase enzyme Nsp13, which is critical for viral replication and is the most conserved non-structural protein within the extended coronavirus family. The goal of this project is to further develop the chemical structure of the preclinical candidate EIS4363 and to further increase the efficacy in animal models. Additional research will be directed toward developing a highly effective, oral combination therapy with drugs targeting the RNA-dependent RNA polymerase (RdRP), such as molnupiravir.
"We are very proud that a start-up from the IZB is making a significant contribution to the global fight against the Corona pandemic. Thus, we wish the team of Eisbach Bio much success in the implementation of their innovative technology," comments Dr. Peter Hanns Zobel, Managing Director of the IZB, the positive development of the company.
Captures:
Photo 1: Dr. Adrian Schomburg, CEO Eisbach Bio GmbH
Photo 2: Dr. Andreas Ladurner, CSO und Dr. Adrian Schomburg, CEO Eisbach Bio GmbH
About Innovation and Start-up Center for Biotechnology (IZB) in Martinsried near Munich
The Fördergesellschaft IZB mbH, founded in 1995, is the operating company of the Innovation and Start-up Centers for Biotechnology in Planegg-Martinsried and Freising-Weihenstephan, and has developed into a leading biotechnology center in Europe. More than 50 biotech companies with over 700 employees are currently located on 26,000 m2 of land. Here, work focuses on the development of drugs against the most serious diseases, such as cancer, Alzheimer's and various autoimmune diseases. A key criterion for the success of the IZBs is their close proximity to top-level research at both the Martinsried/Grosshadern campus and the Weihenstephan campus. The new infrastructure measures such as the Faculty Club G2B (Gateway to Biotech), the IZB Residence CAMPUS AT HOME, the Elhardt Chemistry College, the two kindergartens Bio Kids and Bio Kids2, as well as the two restaurants SEVEN AND MORE and Café Freshmaker are also location factors that are highly appreciated by the company founders. Successful companies that have emerged from the IZB include Medigene AG, MorphoSys AG, Micromet GmbH (today Amgen AG), Octopharma GmbH, Corimmun (today Janssen-Cilag), Rigontec GmbH (today MSD), ibidi GmbH, Coriolis GmbH and Immunic Therapeutics. More information at www.izb-online.de
Press contact and image requests:
Susanne Simon, Head of Public Relations
Fördergesellschaft IZB mbH, Am Klopferspitz 19, D-82152 Planegg Martinsried
Phone: +49 (0)89/55 279 48-17,
E-mail: simon@izb-online.de: Website: www.izb-online.de
About Eisbach Bio GmbH:
Eisbach develops novel drugs that disrupt molecular machines essential to tumors with defined genetic vulnerabilities in the context of DNA damage and repair (DDR). Its proprietary allosteric platform creates targeted therapies that exploit disease-relevant vulnerabilities. By shutting off the machine’s engine using allosteric inhibitors, Eisbach’s medicines are designed to prevent the reorganization and evolution of cancer genomes. In early 2020, Eisbach joined the global effort to fight the COVID-19 pandemic by exploiting its allosteric platform for the identification of small molecule antivirals targeting related molecular machines and engines in SARS-CoV-2. Founded in 2019, Eisbach is privately held and backed by international investors. For more information, please visit www.eisbach.bio.
More information:
Eisbach Bio GmbH
Email: info@eisbach.bio
Managing Director: Dr. Peter Hanns Zobel Munich Local Court HRB 111930 The information transmitted is intended only for the person to which it is addressed and may contain confidential and/or privileged material. Any retransmission, dissemination or other use of, or taking of any action in reliance upon, this information by persons other than the intended recipient is prohibited. If you received this in error, please contact the sender and delete the material from any computer. Thank you!
